United States:
Live From JPM: Collaboration Or Consternation, The State Of Digital Heath Devices - A Conversation With Mcdermott's Digital Health Thought Leaders
11 January 2018
McDermott Will & Emery
To print this article, all you need is to be registered or login on Mondaq.com.
The proliferation of digital health devices and solutions is at
hand. Demand exists around every corner with applications ranging
from personal wellness to remote patient monitoring. They are being
offered by industry stalwarts and upstarts alike. Collaborations
amongst tech companies, academics, big data providers,
entrepreneurs and traditional healthcare players—all of whom
bring something valuable to the table and all of whom want to be
involved in delivering solutions that can help predict, prevent or
more effectively respond to disease—are catalyzing digital
health product and service development. These new relationships are
bringing the power of multiple competencies and game-changing
perspectives to today's health care challenges. They have the
potential to revolutionize the way we approach health care
delivery. The question is: do these players really know what it
will take to work together successfully and, if so, will they be
able to get digital health solutions over the finish line?
Listen to McDermott's Digital Health thought
leaders share their perspectives on the proliferation of digital
devices and what it means to the marketplace
today.
Live From JPM: Collaboration Or Consternation, The State Of Digital
Heath Devices - A Conversation With Mcdermott's Digital Health
Thought Leaders
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States
Healthcare Policy Developments To Watch In 2024
Crowell & Moring LLP
The ever-changing healthcare policy landscape will witness at the federal level regulatory changes driven by the need to transform healthcare delivery, quality and innovation.
The FDA And The Future Of AI Oversight
Manatt, Phelps & Phillips LLP
In January 2024, the U.S. Government Accountability Office (GAO) issued a report highlighting current obstacles to the U.S. Food and Drug Administration's (FDA) timely and effective regulation...